Clinical Trials
12 trialsNCT06926868 2026-04-30
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07294508 2026-03-20
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai Henlius Biotech
Phase 2/3 Recruiting
NCT05766891 2026-03-16
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
M.D. Anderson Cancer Center
Phase 2/3 Recruiting
NCT07373782 2026-01-28
Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer
Universitaire Ziekenhuizen KU Leuven
Phase 2/3 Recruiting
NCT05860465 2026-01-14
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3 Recruiting
NCT07310758 2025-12-30
Contrast-enhanced Ultrasound for Sentinel Node Detection
The Netherlands Cancer Institute
Phase 2/3 Recruiting
NCT05744687 2025-08-17
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3 Recruiting
NCT05288777 2025-04-18
Breast53
University of Virginia
Phase 2/3 Recruiting
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT05804916 2023-04-07
Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
Peking Union Medical College Hospital
Phase 2/3 Recruiting
NCT04803539 2023-02-21
Artemis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3 Recruiting
NCT03150576 2022-11-14
PARTNER
Cambridge University Hospitals NHS Foundation Trust
Phase 2/3 Recruiting